This pattern was corroborated in the validation cohorts, whereby the most aggressive molecular or methylation groups (MG3 and MG4 for Tubingen, MenG C for Bayley et al., and HM for Choudhury et al.)consistently had both the highest proportion of CDKN2Ahigh and CDKN2A deleted meningiomas, in addition to the highest overall levels of CDKN2A expression (Fig. 3b–d). The gene discussed is CDKN2A; the disease is meningioma.